世界の個別化がん医療市場の成長(現状と展望)2023-2029年Global Personalized Cancer Medicine Market Growth (Status and Outlook) 2023-2029 LPI(LPインフォメーション)の最新調査によると、個別化がん治療薬の世界市場規模は2022年に1581億8000万米ドルとなった。下流市場での需要拡大に伴い、個別化がん治療薬は2029年までに371130万米ドルの再調整規... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリーLPI(LPインフォメーション)の最新調査によると、個別化がん治療薬の世界市場規模は2022年に1581億8000万米ドルとなった。下流市場での需要拡大に伴い、個別化がん治療薬は2029年までに371130万米ドルの再調整規模になると予測され、レビュー期間中のCAGRは13.0%である。この調査レポートは、世界の個別化がん治療薬市場の成長可能性を明らかにしている。個別化がん治療薬は、今後の市場において安定した成長を示すと予想される。しかし、個別化がん治療薬の普及には、製品の差別化、コスト削減、サプライチェーンの最適化が引き続き重要である。市場参入企業は、研究開発への投資、戦略的パートナーシップの構築、進化する消費者の嗜好に合わせた製品提供など、個別化がん医療市場がもたらす莫大な機会を活用する必要がある。 個別化がん医療は、標的治療薬や精密医薬品としても知られ、個々の患者のがんに特有の遺伝的・分子的特徴を特異的に標的とするように設計された医薬品である。これらの薬剤は個別化がん医療の中心的な要素であり、患者の腫瘍のゲノムおよび分子プロファイリングに基づいて選択される。 免疫療法:伝統的な標的療法ではないが、免疫チェックポイント阻害剤のような免疫療法も個別化がん治療の一つである。これらの薬剤は、がん細胞を認識し攻撃するために患者の免疫系を強化し、腫瘍の分子的特徴に基づいて患者に合わせることができる。 個別化がん治療薬は、がん専門医が各患者のがんの特徴に合わせて治療計画を立てることを可能にし、がん治療に革命をもたらした。このアプローチは、予後を改善し、従来のがん治療に伴う副作用を軽減する上で大きな期待が寄せられている。しかし、標的療法のレパートリーを拡大し、より多くのがん患者が利用できるようにするためには、継続的な研究と進歩が必要である。 世界市場において、精密がん医療(個別化がん医療)の中心的メーカーは、アッヴィ、ジョンソン・エンド・ジョンソン、ノバルティスなどである。この業界では上位3社が市場シェアの約30%を占めている。北米、欧州、アジア太平洋地域がこの製品の主要製造地域で、北米が世界市場シェアの50%以上を占めている。同製品は、治療法によって免疫療法薬と標的治療薬に分類される。同製品は、肺がん、乳がん、前立腺がん、血液がんなどの治療に広く使用されている。 主な特徴 個別化がん治療薬市場に関する本レポートは、様々な側面を反映し、業界に関する貴重な洞察を提供します。 市場規模と成長:この調査レポートは、個別化がん治療薬市場の現在の規模と成長の概要を提供します。過去データ、方法別市場細分化(がん免疫療法、標的療法など)、地域別細分化などが含まれます。 市場促進要因と課題:政府規制、環境問題、技術進歩、消費者嗜好の変化など、個別化がん治療薬市場の成長を促進する要因を特定・分析することができる。また、インフラストラクチャーの制約、射程距離への不安、初期コストの高さなど、業界が直面する課題も浮き彫りにすることができる。 競合情勢:この調査レポートは、個別化がん医療市場における競合状況の分析を提供しています。主要企業のプロフィール、市場シェア、戦略、製品提供などが含まれる。また、新興プレーヤーとその市場に与える潜在的な影響にもスポットを当てることができる。 技術開発:この調査レポートは、個別化がん治療薬業界における最新の技術開発を掘り下げることができます。これには、個別化がん治療薬技術の進歩、個別化がん治療薬の新規参入、個別化がん治療薬の新規投資、個別化がん治療薬の将来を形作るその他の技術革新が含まれる。 川下の事業者の好み:本レポートは、個別化がん医療市場における顧客の購買行動と採用動向を明らかにすることができる。このレポートには、顧客の購買決定、個別化がん医療製品の嗜好に影響を与える要因が含まれている。 政府の政策とインセンティブこの調査レポートは、政府の政策やインセンティブが個別化がん医療市場に与える影響を分析している。これには、規制の枠組み、補助金、税制優遇措置、その他個別化がん医療市場の促進を目的とした施策の評価が含まれる。また、市場成長促進におけるこれらの政策の有効性も評価する。 環境への影響と持続可能性この調査レポートは、個別化がん医療市場の環境への影響と持続可能性の側面を評価しています。 市場予測と将来展望:実施した分析に基づき、調査レポートは個別化がん治療薬産業の市場予測と展望を提供する。これには、市場規模、成長率、地域動向、技術進歩や政策展開に関する予測などが含まれる。 提言と機会本レポートは、業界関係者、政策立案者、投資家への提言で締めくくられている。市場関係者が新たなトレンドを活用し、課題を克服し、個別化がん医療市場の成長と発展に貢献するための潜在的な機会を強調しています。 市場細分化: 個別化がん医療市場は、方法別と用途別に分割される。2018年から2029年までの期間について、セグメント間の成長により、方法別、用途別の消費額の正確な計算と予測を提供します。 方法別セグメント がん免疫療法 標的療法 用途別セグメント 肺がん 乳がん 前立腺がん 血液関連癌 その他 本レポートではまた、市場を地域別に分けています: 南北アメリカ アメリカ カナダ メキシコ ブラジル APAC 中国 日本 韓国 東南アジア インド オーストラリア ヨーロッパ ドイツ フランス 英国 イタリア ロシア 中東・アフリカ エジプト 南アフリカ イスラエル トルコ GCC諸国 以下の企業は、主要な専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。 アッヴィ ジョンソン・エンド・ジョンソン ノバルティス ギリアド・サイエンシズ ロシュ ブリストル・マイヤーズ スクイブ アムジェン アストラゼネカ メルク・アンド・カンパニー 武田薬品工業 メルクKGaA セーゲン イーライリリー 小野薬品工業 ファイザー ジーエスケー エクセリクシス リジェネロン イノベント 恒瑞医薬 目次1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Personalized Cancer Medicine Market Size 2018-2029 2.1.2 Personalized Cancer Medicine Market Size CAGR by Region 2018 VS 2022 VS 2029 2.2 Personalized Cancer Medicine Segment by Method 2.2.1 Cancer Immunotherapy 2.2.2 Targeted Therapy 2.3 Personalized Cancer Medicine Market Size by Method 2.3.1 Personalized Cancer Medicine Market Size CAGR by Method (2018 VS 2022 VS 2029) 2.3.2 Global Personalized Cancer Medicine Market Size Market Share by Method (2018-2023) 2.4 Personalized Cancer Medicine Segment by Application 2.4.1 Lung Cancer 2.4.2 Breast Cancer 2.4.3 Prostate Cancer 2.4.4 Blood-related Cancer 2.4.5 Other 2.5 Personalized Cancer Medicine Market Size by Application 2.5.1 Personalized Cancer Medicine Market Size CAGR by Application (2018 VS 2022 VS 2029) 2.5.2 Global Personalized Cancer Medicine Market Size Market Share by Application (2018-2023) 3 Personalized Cancer Medicine Market Size by Player 3.1 Personalized Cancer Medicine Market Size Market Share by Players 3.1.1 Global Personalized Cancer Medicine Revenue by Players (2018-2023) 3.1.2 Global Personalized Cancer Medicine Revenue Market Share by Players (2018-2023) 3.2 Global Personalized Cancer Medicine Key Players Head office and Products Offered 3.3 Market Concentration Rate Analysis 3.3.1 Competition Landscape Analysis 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023) 3.4 New Products and Potential Entrants 3.5 Mergers & Acquisitions, Expansion 4 Personalized Cancer Medicine by Regions 4.1 Personalized Cancer Medicine Market Size by Regions (2018-2023) 4.2 Americas Personalized Cancer Medicine Market Size Growth (2018-2023) 4.3 APAC Personalized Cancer Medicine Market Size Growth (2018-2023) 4.4 Europe Personalized Cancer Medicine Market Size Growth (2018-2023) 4.5 Middle East & Africa Personalized Cancer Medicine Market Size Growth (2018-2023) 5 Americas 5.1 Americas Personalized Cancer Medicine Market Size by Country (2018-2023) 5.2 Americas Personalized Cancer Medicine Market Size by Method (2018-2023) 5.3 Americas Personalized Cancer Medicine Market Size by Application (2018-2023) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Personalized Cancer Medicine Market Size by Region (2018-2023) 6.2 APAC Personalized Cancer Medicine Market Size by Method (2018-2023) 6.3 APAC Personalized Cancer Medicine Market Size by Application (2018-2023) 6.4 China 6.5 Japan 6.6 Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 7 Europe 7.1 Europe Personalized Cancer Medicine by Country (2018-2023) 7.2 Europe Personalized Cancer Medicine Market Size by Method (2018-2023) 7.3 Europe Personalized Cancer Medicine Market Size by Application (2018-2023) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Personalized Cancer Medicine by Region (2018-2023) 8.2 Middle East & Africa Personalized Cancer Medicine Market Size by Method (2018-2023) 8.3 Middle East & Africa Personalized Cancer Medicine Market Size by Application (2018-2023) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Global Personalized Cancer Medicine Market Forecast 10.1 Global Personalized Cancer Medicine Forecast by Regions (2024-2029) 10.1.1 Global Personalized Cancer Medicine Forecast by Regions (2024-2029) 10.1.2 Americas Personalized Cancer Medicine Forecast 10.1.3 APAC Personalized Cancer Medicine Forecast 10.1.4 Europe Personalized Cancer Medicine Forecast 10.1.5 Middle East & Africa Personalized Cancer Medicine Forecast 10.2 Americas Personalized Cancer Medicine Forecast by Country (2024-2029) 10.2.1 United States Personalized Cancer Medicine Market Forecast 10.2.2 Canada Personalized Cancer Medicine Market Forecast 10.2.3 Mexico Personalized Cancer Medicine Market Forecast 10.2.4 Brazil Personalized Cancer Medicine Market Forecast 10.3 APAC Personalized Cancer Medicine Forecast by Region (2024-2029) 10.3.1 China Personalized Cancer Medicine Market Forecast 10.3.2 Japan Personalized Cancer Medicine Market Forecast 10.3.3 Korea Personalized Cancer Medicine Market Forecast 10.3.4 Southeast Asia Personalized Cancer Medicine Market Forecast 10.3.5 India Personalized Cancer Medicine Market Forecast 10.3.6 Australia Personalized Cancer Medicine Market Forecast 10.4 Europe Personalized Cancer Medicine Forecast by Country (2024-2029) 10.4.1 Germany Personalized Cancer Medicine Market Forecast 10.4.2 France Personalized Cancer Medicine Market Forecast 10.4.3 UK Personalized Cancer Medicine Market Forecast 10.4.4 Italy Personalized Cancer Medicine Market Forecast 10.4.5 Russia Personalized Cancer Medicine Market Forecast 10.5 Middle East & Africa Personalized Cancer Medicine Forecast by Region (2024-2029) 10.5.1 Egypt Personalized Cancer Medicine Market Forecast 10.5.2 South Africa Personalized Cancer Medicine Market Forecast 10.5.3 Israel Personalized Cancer Medicine Market Forecast 10.5.4 Turkey Personalized Cancer Medicine Market Forecast 10.5.5 GCC Countries Personalized Cancer Medicine Market Forecast 10.6 Global Personalized Cancer Medicine Forecast by Method (2024-2029) 10.7 Global Personalized Cancer Medicine Forecast by Application (2024-2029) 11 Key Players Analysis 11.1 AbbVie 11.1.1 AbbVie Company Information 11.1.2 AbbVie Personalized Cancer Medicine Product Offered 11.1.3 AbbVie Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.1.4 AbbVie Main Business Overview 11.1.5 AbbVie Latest Developments 11.2 Johnson & Johnson 11.2.1 Johnson & Johnson Company Information 11.2.2 Johnson & Johnson Personalized Cancer Medicine Product Offered 11.2.3 Johnson & Johnson Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.2.4 Johnson & Johnson Main Business Overview 11.2.5 Johnson & Johnson Latest Developments 11.3 Novartis 11.3.1 Novartis Company Information 11.3.2 Novartis Personalized Cancer Medicine Product Offered 11.3.3 Novartis Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.3.4 Novartis Main Business Overview 11.3.5 Novartis Latest Developments 11.4 Gilead Sciences 11.4.1 Gilead Sciences Company Information 11.4.2 Gilead Sciences Personalized Cancer Medicine Product Offered 11.4.3 Gilead Sciences Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.4.4 Gilead Sciences Main Business Overview 11.4.5 Gilead Sciences Latest Developments 11.5 Roche 11.5.1 Roche Company Information 11.5.2 Roche Personalized Cancer Medicine Product Offered 11.5.3 Roche Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.5.4 Roche Main Business Overview 11.5.5 Roche Latest Developments 11.6 Bristol-Myers Squibb 11.6.1 Bristol-Myers Squibb Company Information 11.6.2 Bristol-Myers Squibb Personalized Cancer Medicine Product Offered 11.6.3 Bristol-Myers Squibb Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.6.4 Bristol-Myers Squibb Main Business Overview 11.6.5 Bristol-Myers Squibb Latest Developments 11.7 Amgen 11.7.1 Amgen Company Information 11.7.2 Amgen Personalized Cancer Medicine Product Offered 11.7.3 Amgen Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.7.4 Amgen Main Business Overview 11.7.5 Amgen Latest Developments 11.8 AstraZeneca 11.8.1 AstraZeneca Company Information 11.8.2 AstraZeneca Personalized Cancer Medicine Product Offered 11.8.3 AstraZeneca Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.8.4 AstraZeneca Main Business Overview 11.8.5 AstraZeneca Latest Developments 11.9 Merck & Co 11.9.1 Merck & Co Company Information 11.9.2 Merck & Co Personalized Cancer Medicine Product Offered 11.9.3 Merck & Co Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.9.4 Merck & Co Main Business Overview 11.9.5 Merck & Co Latest Developments 11.10 Takeda 11.10.1 Takeda Company Information 11.10.2 Takeda Personalized Cancer Medicine Product Offered 11.10.3 Takeda Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.10.4 Takeda Main Business Overview 11.10.5 Takeda Latest Developments 11.11 Merck KGaA 11.11.1 Merck KGaA Company Information 11.11.2 Merck KGaA Personalized Cancer Medicine Product Offered 11.11.3 Merck KGaA Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.11.4 Merck KGaA Main Business Overview 11.11.5 Merck KGaA Latest Developments 11.12 Seagen 11.12.1 Seagen Company Information 11.12.2 Seagen Personalized Cancer Medicine Product Offered 11.12.3 Seagen Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.12.4 Seagen Main Business Overview 11.12.5 Seagen Latest Developments 11.13 Eli Lilly 11.13.1 Eli Lilly Company Information 11.13.2 Eli Lilly Personalized Cancer Medicine Product Offered 11.13.3 Eli Lilly Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.13.4 Eli Lilly Main Business Overview 11.13.5 Eli Lilly Latest Developments 11.14 Ono Pharmaceutical 11.14.1 Ono Pharmaceutical Company Information 11.14.2 Ono Pharmaceutical Personalized Cancer Medicine Product Offered 11.14.3 Ono Pharmaceutical Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.14.4 Ono Pharmaceutical Main Business Overview 11.14.5 Ono Pharmaceutical Latest Developments 11.15 Pfizer 11.15.1 Pfizer Company Information 11.15.2 Pfizer Personalized Cancer Medicine Product Offered 11.15.3 Pfizer Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.15.4 Pfizer Main Business Overview 11.15.5 Pfizer Latest Developments 11.16 GSK 11.16.1 GSK Company Information 11.16.2 GSK Personalized Cancer Medicine Product Offered 11.16.3 GSK Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.16.4 GSK Main Business Overview 11.16.5 GSK Latest Developments 11.17 Exelixis 11.17.1 Exelixis Company Information 11.17.2 Exelixis Personalized Cancer Medicine Product Offered 11.17.3 Exelixis Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.17.4 Exelixis Main Business Overview 11.17.5 Exelixis Latest Developments 11.18 Regeneron 11.18.1 Regeneron Company Information 11.18.2 Regeneron Personalized Cancer Medicine Product Offered 11.18.3 Regeneron Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.18.4 Regeneron Main Business Overview 11.18.5 Regeneron Latest Developments 11.19 Innovent 11.19.1 Innovent Company Information 11.19.2 Innovent Personalized Cancer Medicine Product Offered 11.19.3 Innovent Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.19.4 Innovent Main Business Overview 11.19.5 Innovent Latest Developments 11.20 Hengrui Medicine 11.20.1 Hengrui Medicine Company Information 11.20.2 Hengrui Medicine Personalized Cancer Medicine Product Offered 11.20.3 Hengrui Medicine Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.20.4 Hengrui Medicine Main Business Overview 11.20.5 Hengrui Medicine Latest Developments 12 Research Findings and Conclusion
SummaryAccording to our LPI (LP Information) latest study, the global Personalized Cancer Medicine market size was valued at US$ 158180 million in 2022. With growing demand in downstream market, the Personalized Cancer Medicine is forecast to a readjusted size of US$ 371130 million by 2029 with a CAGR of 13.0% during review period. Table of Contents1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Personalized Cancer Medicine Market Size 2018-2029 2.1.2 Personalized Cancer Medicine Market Size CAGR by Region 2018 VS 2022 VS 2029 2.2 Personalized Cancer Medicine Segment by Method 2.2.1 Cancer Immunotherapy 2.2.2 Targeted Therapy 2.3 Personalized Cancer Medicine Market Size by Method 2.3.1 Personalized Cancer Medicine Market Size CAGR by Method (2018 VS 2022 VS 2029) 2.3.2 Global Personalized Cancer Medicine Market Size Market Share by Method (2018-2023) 2.4 Personalized Cancer Medicine Segment by Application 2.4.1 Lung Cancer 2.4.2 Breast Cancer 2.4.3 Prostate Cancer 2.4.4 Blood-related Cancer 2.4.5 Other 2.5 Personalized Cancer Medicine Market Size by Application 2.5.1 Personalized Cancer Medicine Market Size CAGR by Application (2018 VS 2022 VS 2029) 2.5.2 Global Personalized Cancer Medicine Market Size Market Share by Application (2018-2023) 3 Personalized Cancer Medicine Market Size by Player 3.1 Personalized Cancer Medicine Market Size Market Share by Players 3.1.1 Global Personalized Cancer Medicine Revenue by Players (2018-2023) 3.1.2 Global Personalized Cancer Medicine Revenue Market Share by Players (2018-2023) 3.2 Global Personalized Cancer Medicine Key Players Head office and Products Offered 3.3 Market Concentration Rate Analysis 3.3.1 Competition Landscape Analysis 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023) 3.4 New Products and Potential Entrants 3.5 Mergers & Acquisitions, Expansion 4 Personalized Cancer Medicine by Regions 4.1 Personalized Cancer Medicine Market Size by Regions (2018-2023) 4.2 Americas Personalized Cancer Medicine Market Size Growth (2018-2023) 4.3 APAC Personalized Cancer Medicine Market Size Growth (2018-2023) 4.4 Europe Personalized Cancer Medicine Market Size Growth (2018-2023) 4.5 Middle East & Africa Personalized Cancer Medicine Market Size Growth (2018-2023) 5 Americas 5.1 Americas Personalized Cancer Medicine Market Size by Country (2018-2023) 5.2 Americas Personalized Cancer Medicine Market Size by Method (2018-2023) 5.3 Americas Personalized Cancer Medicine Market Size by Application (2018-2023) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Personalized Cancer Medicine Market Size by Region (2018-2023) 6.2 APAC Personalized Cancer Medicine Market Size by Method (2018-2023) 6.3 APAC Personalized Cancer Medicine Market Size by Application (2018-2023) 6.4 China 6.5 Japan 6.6 Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 7 Europe 7.1 Europe Personalized Cancer Medicine by Country (2018-2023) 7.2 Europe Personalized Cancer Medicine Market Size by Method (2018-2023) 7.3 Europe Personalized Cancer Medicine Market Size by Application (2018-2023) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Personalized Cancer Medicine by Region (2018-2023) 8.2 Middle East & Africa Personalized Cancer Medicine Market Size by Method (2018-2023) 8.3 Middle East & Africa Personalized Cancer Medicine Market Size by Application (2018-2023) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Global Personalized Cancer Medicine Market Forecast 10.1 Global Personalized Cancer Medicine Forecast by Regions (2024-2029) 10.1.1 Global Personalized Cancer Medicine Forecast by Regions (2024-2029) 10.1.2 Americas Personalized Cancer Medicine Forecast 10.1.3 APAC Personalized Cancer Medicine Forecast 10.1.4 Europe Personalized Cancer Medicine Forecast 10.1.5 Middle East & Africa Personalized Cancer Medicine Forecast 10.2 Americas Personalized Cancer Medicine Forecast by Country (2024-2029) 10.2.1 United States Personalized Cancer Medicine Market Forecast 10.2.2 Canada Personalized Cancer Medicine Market Forecast 10.2.3 Mexico Personalized Cancer Medicine Market Forecast 10.2.4 Brazil Personalized Cancer Medicine Market Forecast 10.3 APAC Personalized Cancer Medicine Forecast by Region (2024-2029) 10.3.1 China Personalized Cancer Medicine Market Forecast 10.3.2 Japan Personalized Cancer Medicine Market Forecast 10.3.3 Korea Personalized Cancer Medicine Market Forecast 10.3.4 Southeast Asia Personalized Cancer Medicine Market Forecast 10.3.5 India Personalized Cancer Medicine Market Forecast 10.3.6 Australia Personalized Cancer Medicine Market Forecast 10.4 Europe Personalized Cancer Medicine Forecast by Country (2024-2029) 10.4.1 Germany Personalized Cancer Medicine Market Forecast 10.4.2 France Personalized Cancer Medicine Market Forecast 10.4.3 UK Personalized Cancer Medicine Market Forecast 10.4.4 Italy Personalized Cancer Medicine Market Forecast 10.4.5 Russia Personalized Cancer Medicine Market Forecast 10.5 Middle East & Africa Personalized Cancer Medicine Forecast by Region (2024-2029) 10.5.1 Egypt Personalized Cancer Medicine Market Forecast 10.5.2 South Africa Personalized Cancer Medicine Market Forecast 10.5.3 Israel Personalized Cancer Medicine Market Forecast 10.5.4 Turkey Personalized Cancer Medicine Market Forecast 10.5.5 GCC Countries Personalized Cancer Medicine Market Forecast 10.6 Global Personalized Cancer Medicine Forecast by Method (2024-2029) 10.7 Global Personalized Cancer Medicine Forecast by Application (2024-2029) 11 Key Players Analysis 11.1 AbbVie 11.1.1 AbbVie Company Information 11.1.2 AbbVie Personalized Cancer Medicine Product Offered 11.1.3 AbbVie Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.1.4 AbbVie Main Business Overview 11.1.5 AbbVie Latest Developments 11.2 Johnson & Johnson 11.2.1 Johnson & Johnson Company Information 11.2.2 Johnson & Johnson Personalized Cancer Medicine Product Offered 11.2.3 Johnson & Johnson Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.2.4 Johnson & Johnson Main Business Overview 11.2.5 Johnson & Johnson Latest Developments 11.3 Novartis 11.3.1 Novartis Company Information 11.3.2 Novartis Personalized Cancer Medicine Product Offered 11.3.3 Novartis Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.3.4 Novartis Main Business Overview 11.3.5 Novartis Latest Developments 11.4 Gilead Sciences 11.4.1 Gilead Sciences Company Information 11.4.2 Gilead Sciences Personalized Cancer Medicine Product Offered 11.4.3 Gilead Sciences Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.4.4 Gilead Sciences Main Business Overview 11.4.5 Gilead Sciences Latest Developments 11.5 Roche 11.5.1 Roche Company Information 11.5.2 Roche Personalized Cancer Medicine Product Offered 11.5.3 Roche Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.5.4 Roche Main Business Overview 11.5.5 Roche Latest Developments 11.6 Bristol-Myers Squibb 11.6.1 Bristol-Myers Squibb Company Information 11.6.2 Bristol-Myers Squibb Personalized Cancer Medicine Product Offered 11.6.3 Bristol-Myers Squibb Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.6.4 Bristol-Myers Squibb Main Business Overview 11.6.5 Bristol-Myers Squibb Latest Developments 11.7 Amgen 11.7.1 Amgen Company Information 11.7.2 Amgen Personalized Cancer Medicine Product Offered 11.7.3 Amgen Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.7.4 Amgen Main Business Overview 11.7.5 Amgen Latest Developments 11.8 AstraZeneca 11.8.1 AstraZeneca Company Information 11.8.2 AstraZeneca Personalized Cancer Medicine Product Offered 11.8.3 AstraZeneca Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.8.4 AstraZeneca Main Business Overview 11.8.5 AstraZeneca Latest Developments 11.9 Merck & Co 11.9.1 Merck & Co Company Information 11.9.2 Merck & Co Personalized Cancer Medicine Product Offered 11.9.3 Merck & Co Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.9.4 Merck & Co Main Business Overview 11.9.5 Merck & Co Latest Developments 11.10 Takeda 11.10.1 Takeda Company Information 11.10.2 Takeda Personalized Cancer Medicine Product Offered 11.10.3 Takeda Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.10.4 Takeda Main Business Overview 11.10.5 Takeda Latest Developments 11.11 Merck KGaA 11.11.1 Merck KGaA Company Information 11.11.2 Merck KGaA Personalized Cancer Medicine Product Offered 11.11.3 Merck KGaA Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.11.4 Merck KGaA Main Business Overview 11.11.5 Merck KGaA Latest Developments 11.12 Seagen 11.12.1 Seagen Company Information 11.12.2 Seagen Personalized Cancer Medicine Product Offered 11.12.3 Seagen Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.12.4 Seagen Main Business Overview 11.12.5 Seagen Latest Developments 11.13 Eli Lilly 11.13.1 Eli Lilly Company Information 11.13.2 Eli Lilly Personalized Cancer Medicine Product Offered 11.13.3 Eli Lilly Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.13.4 Eli Lilly Main Business Overview 11.13.5 Eli Lilly Latest Developments 11.14 Ono Pharmaceutical 11.14.1 Ono Pharmaceutical Company Information 11.14.2 Ono Pharmaceutical Personalized Cancer Medicine Product Offered 11.14.3 Ono Pharmaceutical Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.14.4 Ono Pharmaceutical Main Business Overview 11.14.5 Ono Pharmaceutical Latest Developments 11.15 Pfizer 11.15.1 Pfizer Company Information 11.15.2 Pfizer Personalized Cancer Medicine Product Offered 11.15.3 Pfizer Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.15.4 Pfizer Main Business Overview 11.15.5 Pfizer Latest Developments 11.16 GSK 11.16.1 GSK Company Information 11.16.2 GSK Personalized Cancer Medicine Product Offered 11.16.3 GSK Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.16.4 GSK Main Business Overview 11.16.5 GSK Latest Developments 11.17 Exelixis 11.17.1 Exelixis Company Information 11.17.2 Exelixis Personalized Cancer Medicine Product Offered 11.17.3 Exelixis Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.17.4 Exelixis Main Business Overview 11.17.5 Exelixis Latest Developments 11.18 Regeneron 11.18.1 Regeneron Company Information 11.18.2 Regeneron Personalized Cancer Medicine Product Offered 11.18.3 Regeneron Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.18.4 Regeneron Main Business Overview 11.18.5 Regeneron Latest Developments 11.19 Innovent 11.19.1 Innovent Company Information 11.19.2 Innovent Personalized Cancer Medicine Product Offered 11.19.3 Innovent Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.19.4 Innovent Main Business Overview 11.19.5 Innovent Latest Developments 11.20 Hengrui Medicine 11.20.1 Hengrui Medicine Company Information 11.20.2 Hengrui Medicine Personalized Cancer Medicine Product Offered 11.20.3 Hengrui Medicine Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023) 11.20.4 Hengrui Medicine Main Business Overview 11.20.5 Hengrui Medicine Latest Developments 12 Research Findings and Conclusion
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医薬)の最新刊レポート
LP Information社の医薬品・ヘルスケア分野での最新刊レポート
本レポートと同じKEY WORD(cancer)の最新刊レポート
よくあるご質問LP Information社はどのような調査会社ですか?LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/12/23 10:26 157.72 円 164.94 円 201.11 円 |